New peer-reviewed paper reveals new findings that can lead to more effective medicines for a range of health conditions BOSTON, Feb. 16, 2023 /PRNewswire/ — Delix Therapeutics (the “Company”), a neuroscience company developing novel disease-modifying, neuroplasticity-promoting therapeutics for psychiatric and neurological conditions, shared the findings of a new study published today in Science.


Previous articlePT390 – Vital Psychedelic Conversations
Next articleNuminus Expands Research Capabilities with new Phoenix Clinical Research Site